Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Colorectal Neoplasms 56Rectal Neoplasms 30Colonic Neoplasms 29Pancreatic Neoplasms 28Neoplasms 20Neoplasm Metastasis 18Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 14Unspecified Adult Solid Tumor, Protocol Specific 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid, Acute 8Esophageal Neoplasms 8Ovarian Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma 7Adenocarcinoma 7Myelodysplastic Syndromes 6Lung Neoplasms 6Gallbladder Neoplasms 6Breast Neoplasms 6Sarcoma 5Osteosarcoma 5Liver Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Bile Duct Neoplasms 5Triple Negative Breast Neoplasms 4Solid Tumor 4

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Leucovorin × Clear all
NCT02015819 2021-10-20

Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas

City of Hope Medical Center

Phase 1 Completed
16 enrolled 16 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡